Pancreatic Cancer Research

ResearcherOslo University HospitalNo recent work listed

Einar K. Rofstad

Verified by OpenAlex author ID (good confidence, 0.85), identity_conf@1As of 7 November 2026

Matched on OpenAlex author ID A5105416895. Sources: OpenAlex.

Their work

Papers
6 (first author 1, last author 5)
Trials
0
Grants
0
Labs led
1
Collaborators
6
Papers, trials and grants by year

2016: 1 paper · 2017: 2 papers · 2018: 1 paper · 2019: 1 paper · 2020: none · 2021: none · 2022: 1 paper

Papers 6

  1. Fluid-sensitive migration mechanisms predict association between metastasis and high interstitial fluid pressure in pancreatic cancer. First author DOI 10.1016/j.jbiomech.2022.111362↗
  2. Vascularization, Oxygenation, and the Effect of Sunitinib Treatment in Pancreatic Ductal Adenocarcinoma Xenografts. Last author DOI 10.3389/fonc.2019.00845↗
  3. DCE-MRI of Sunitinib-Induced Changes in Tumor Microvasculature and Hypoxia: A Study of Pancreatic Ductal Adenocarcinoma Xenografts. Last author DOI 10.1016/j.neo.2018.05.006↗
  4. Dynamic contrast-enhanced MRI of the microenvironment of pancreatic adenocarcinoma xenografts. Last author DOI 10.1080/0284186x.2017.1343494↗
  5. Lymph node metastasis and the physicochemical micro-environment of pancreatic ductal adenocarcinoma xenografts. Last author DOI 10.18632/oncotarget.18231↗
  6. Diffusion-weighted and dynamic contrast-enhanced MRI of pancreatic adenocarcinoma xenografts: associations with tumor differentiation and collagen content. Last author DOI 10.1186/s12967-016-0920-y↗

Closest collaborators

The 6 strongest of 6 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Catherine Sem Wegner · 5 shared papers, 2016–2019 · strength 0.46
  2. Jon‐Vidar Gaustad · 5 shared papers, 2016–2019 · strength 0.46
  3. Lise Mari K. Andersen · 4 shared papers, 2016–2018 · strength 0.32
  4. Steinar Evje · 1 shared paper, 2022 · strength 0.22
  5. Geir Nævdal · 1 shared paper, 2022 · strength 0.22
  6. Kjetil Søreide · 1 shared paper, 2022 · strength 0.22

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.